MedTrace Logo

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

NCT05335044 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-06-09

No results posted yet for this study

Summary

Phase 1 study to evaluate the safety and pharmacokinetics of CKD-331 in healthy adult volunteers

Conditions

  • Hypertension and Dyslipidemia

Interventions

DRUG

CKD-331

QD, PO

DRUG

EX5619

QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Jaewoo Kim, M.D., PhD. · Yanhji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2022-06-23
Completion
2022-07-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05335044 on ClinicalTrials.gov